Bicara Therapeutics Inc
BCAXHealthcare|Biotechnology|USA
$28.88
-0.77 (-2.59%)
Tangible Book
$7.84
Upcoming Data Readouts (3)
Dec 2026
Est. completion
P1Head and Neck Squamous Cell Carcinoma
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542n=292
Apr 2028
Est. completion
P2P3Metastatic Head and Neck Squamous Cell Carcinoma
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990n=650
Apr 2028
Est. completion
P2Head and Neck Squamous Cell Carcinoma (HNSCC)
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
NCT07465276n=32